The antidepressant Prozac may help to curb disease activity in the relapsing remitting form of multiple sclerosis (MS), reveals preliminary research published ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.
The research team randomly allocated 40 patients with the relapsing remitting form of MS to treatment with either 20 mg daily of fluoxetine (Prozac) or an inactive substance (placebo) for a period of 24 weeks.
Detailed brain scans (magnetic resonance images or MRI) every four weeks were used to check for new areas of neurological inflammation, a hallmark of active disease.
In total, 38 patients-19 in each group-completed the study. The scans showed that those in the placebo group had more new areas of inflammation than those treated with Prozac.............
For the full report please go to
MSRC: MS Research News : Drugs : Further Possible MS Drugs and Treatments
Your Charity Space
